Evidence map›Paper›PMID 35243951›Full record

ArticleDrug delivery2022

Development and optimization of curcumin analog nano-bilosomes using 2

Haidy Abbas, Yasmin A El-Feky, Majid Mohammad Al-Sawahli, Nehal M El-Deeb, Hala Bakr El-Nassan, Mariam Zewail

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Chinese herbal medicines · 2025
    Review
  5. Article
  6. Article
  7. In-vivo and in-vitro assessment of curcumin loaded bile salt stabilized nanovesicles for oral delivery.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. NovelPharmaceuticals (Basel, Switzerland) · 2022
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Haidy AbbasPharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhur, Egypt.
Yasmin A El-FekyDepartment of Pharmaceutics, Faculty of Pharmacy, Modern University for Technology and Information (MTI), Cairo, Egypt.
Majid Mohammad Al-SawahliDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Kafr Elsheikh University, Kafr Elsheikh, Egypt.
Nehal M El-DeebBiopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications, Alexandria, Egypt.
Hala Bakr El-NassanPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Mariam ZewailPharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhur, Egypt.
Damanhour University · EGCairo University · EGCity of Scientific Research and Technological Applications · EGIraqi University · IQModern University for Information and Technology · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin (CU) is a natural polyphenolic phytoingredient. CU has anti-inflammatory, anti-oxidant, and anticancer activities. The poor solubility, bioavailability, and stability of CU diminish its clinical application. Hence, structural modification of CU is highly recommended. The CU analog; 3,5-bis(4-bromobenzylidene)-1-propanoylpiperidin-4-one (PIP) exhibited high stability, safety, and more potent antiproliferative activity against hepatocellular carcinoma. In the present study, nano-bilosomes (BLs) were formulated to augment PIP delivery and enhance its solubility. A 2

Indexed as

Carcinoma, HepatocellularCurcuminLiver NeoplasmsNanoparticlesBiological AvailabilityDoxorubicinHumansCurcuminDoxorubicin3,5-bis(4-bromobenzylidene)-1-propanoylpiperidin-4-onebile saltsCurcuminhepatocellular carcinomanano-bilosomes

Identifiers

PMID35243951
PMCPMC8903797
OpenAlexW4214892256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.